Non‐Hodgkin lymphoma following temozolomide
Atul Sharma(DR. B.R.A. Institute Rotary Cancer Hospital), Deepak Gupta(DR. B.R.A. Institute Rotary Cancer Hospital), Bidhu Kalyan Mohanti(DR. B.R.A. Institute Rotary Cancer Hospital), Sanjay Thulkar(DR. B.R.A. Institute Rotary Cancer Hospital), Amit Dutt Dwary(DR. B.R.A. Institute Rotary Cancer Hospital), Shikha Goyal(DR. B.R.A. Institute Rotary Cancer Hospital), Sandeep Muzumder(DR. B.R.A. Institute Rotary Cancer Hospital), Prasenjit Das(DR. B.R.A. Institute Rotary Cancer Hospital)
Cited by 16
Abstract
Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma. It increases survival by 2.5 months when used in combination with radiotherapy as an adjuvant therapy in GBM. Secondary MDS/AML or non-Hodgkin lymphoma attributed to TMZ exposure has been reported. We report a case of non-Hodgkin lymphoma secondary to temozolomide in a 20-year-old female who was treated for GBM with concurrent TMZ and radiotherapy. She developed lymphoma 2 months after completing chemoradiotherapy. Although she was treated with combination chemotherapy for lymphoma, she died of progressive GBM.
Related Papers
No related papers found
Powered by citation graph analysis